Beam Therapeutics Inc. (BEAM): Results of Operations and Financial Condition
Beam Therapeutics Inc. (BEAM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD) Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation
How this was made
The 30-second read
Why it matters
The filing combines (1) cash runway into mid-2029, (2) clinical execution milestones (first pivotal cohort dose for BEAM-302, dosing completion for BEACON risto-cel), and (3) regulatory progress (FDA IND clearance for BEAM-304), plus (4) a stated expectation for risto-cel BLA submission by year-end 2026.
Market read
Traders can use this update to reassess near-term probability-weighted timelines for BEAM-302 pivotal execution, ERS catalyst timing, and risto-cel BLA submission, while monitoring cash burn and dilution risk.
What to watch
Cash runway extends to mid-2029, but dilution risk and trial execution risk remain, especially if pivotal enrollment or BLA preparation slips beyond the stated year-end 2026 window.
Beam Therapeutics reported second quarter 2026 results, dosed the first patient in the BEAM-302 global pivotal cohort, and completed dosing in the adult and adolescent BEACON trial population for risto-cel.
Clinical and regulatory execution advanced across BEAM-302, risto-cel and BEAM-304, while net loss was $122.7 million versus $102.1 million in the second quarter of 2025 and the balance-sheet table reported cash, cash equivalents, and marketable securities of $1,152,927 as of June 30, 2026.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Cash, cash equivalents and marketable securitiesother | $1.2 billion | – | – |
| Research & Development (R&D) Expensesother | $95.1 million | – | – |
| General & Administrative (G&A) Expensesother | $31.9 million | – | – |
| Net lossother | $122.7 million | – | – |
| Net loss per shareother | $1.18 per share | – | – |
| Cash, cash equivalents, and marketable securitiesother | $ 1,152,927 | – | – |
| Total assetsother | 1,386,355 | – | – |
| Total liabilitiesother | 318,913 | – | – |
| Total stockholders’ equityother | 1,067,442 | – | – |
2026 and into mid-2029 outlook
- NoteCash, cash equivalents and marketable securities as of June 30, 2026, together with an additional $200 million expected to be drawn from the company’s facility with Sixth Street, will fund anticipated operating expenses and capital expenditure requirements into mid-2029.
- NoteBeam expects to report initial clinical data for BEAM-301 in 2026.
- NoteBeam expects to report updated data for the BEACON trial by year-end 2026 and submit a biologics license application (BLA) for risto-cel as early as year-end 2026.
- NoteDetailed and updated clinical data for BEAM-302 were selected for a late-breaking oral presentation at the European Respiratory Society (ERS) Congress, taking place September 5-9, 2026.
What drove it
- Beam dosed the first patient in the global pivotal cohort of the Phase 1/2 BEAM-302 trial in July.
- Dosing is complete in all adult and adolescent patients enrolled in the Phase 1/2 BEACON trial of risto-cel.
- The U.S. Food and Drug Administration cleared the investigational new drug application for BEAM-304 in June, and Beam initiated clinical start-up activities for the planned Phase 1/2 trial.
- Beam completed enrollment and dosing in the Phase 1 healthy volunteer clinical trial of BEAM-103; treatment was well tolerated across all doses tested.
Concerns
- Net loss was $122.7 million, or $1.18 per share, compared to net loss of $102.1 million, or $1.00 per share, for the second quarter of 2025.
- G&A expenses were $31.9 million, compared to $26.9 million for the second quarter of 2025.
- The cash-runway expectation includes an additional $200 million expected to be drawn from the company’s facility with Sixth Street.
- The BLA submission for risto-cel is expected as early as year-end 2026, and the BEAM-302 cohort is designed to support a potential accelerated approval path rather than representing an approval.
What to watch
- Detailed and updated BEAM-302 clinical data at the ERS Congress, taking place September 5-9, 2026.
- Rapid enrollment in the BEAM-302 pivotal cohort.
- Initial clinical data for BEAM-301 in 2026.
- Updated BEACON trial data by year-end 2026.
- Potential BLA submission for risto-cel as early as year-end 2026.
- Clinical start-up and planned Phase 1/2 execution for BEAM-304.
Balance sheet and cash flow
- Cash, cash equivalents, and marketable securities were $1.2 billion as of June 30, 2026, compared to $1.2 billion as of December 31, 2025.
- Cash, cash equivalents, and marketable securities were $ 1,152,927 as of June 30, 2026, compared to $ 1,245,210 as of December 31, 2025.
- Total assets were 1,386,355 as of June 30, 2026, compared to 1,481,177 as of December 31, 2025.
- Total liabilities were 318,913 as of June 30, 2026, compared to 242,819 as of December 31, 2025.
- Total stockholders’ equity was 1,067,442 as of June 30, 2026.
- An additional $200 million is expected to be drawn from the company’s facility with Sixth Street.
Analysis
Beam’s reported quarter was defined by pipeline execution rather than commercial financial performance. The company dosed the first patient in the global pivotal cohort for BEAM-302 in July, completed dosing of adult and adolescent patients in the Phase 1/2 BEACON trial of risto-cel, and received FDA clearance of the IND for BEAM-304 in June. The BEAM-302 cohort is intended to support a potential accelerated approval path in the United States, while BEAM-304 has entered clinical start-up activities for its planned Phase 1/2 trial.
Expense and loss data show continued investment in development programs. R&D expenses were $95.1 million for the second quarter of 2026, compared with $101.8 million for the second quarter of 2025. G&A expenses were $31.9 million, compared with $26.9 million. Net loss was $122.7 million, or $1.18 per share, compared with net loss of $102.1 million, or $1.00 per share, in the prior-year quarter.
Liquidity remains the central financial support for the clinical plan. The press release stated cash, cash equivalents and marketable securities of $1.2 billion as of June 30, 2026, compared with $1.2 billion as of December 31, 2025. The condensed consolidated balance-sheet table reported cash, cash equivalents, and marketable securities of $ 1,152,927 at June 30, 2026, versus $ 1,245,210 at December 31, 2025, with total liabilities of 318,913 at June 30, 2026. Management expects available cash together with an additional $200 million expected to be drawn from the Sixth Street facility to fund operating expenses and capital expenditure requirements into mid-2029.
The upcoming catalyst sequence is concentrated in clinical data and regulatory activity. Updated BEAM-302 data are scheduled for the ERS Congress on September 5-9, 2026. Beam also expects initial BEAM-301 clinical data in 2026, updated BEACON data by year-end 2026, and a risto-cel BLA submission as early as year-end 2026. Execution against these events, including enrollment of the BEAM-302 pivotal cohort and the use of the Sixth Street facility, is central to the stated operating plan.
Management, verbatim
The second quarter marked another period of rapid progress and disciplined execution on the clinical, regulatory and operational milestones we set for Beam.
John Evans, chief executive officer of Beam Therapeutics
Not in the filing
stated, not guessed- Total revenue
- Revenue prior-year comparison
- Revenue prior-quarter comparison
- Revenue growth
- Segment revenue and segment comparisons
- Gross profit
- Gross margin
- Operating income or loss
- Operating margin
- Non-GAAP financial measures
- Income tax expense or benefit
- Tax rate
- Diluted weighted-average shares
- Operating cash flow
- Free cash flow
- Capital expenditures
- Debt balance
- Share repurchases
- Dividends
- Prior-period outlook for guidance comparison
- Explicit financial guidance for revenue, gross margin, operating expenses, or tax rate
- Total stockholders’ equity as of December 31, 2025
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
This is an SEC Form 8-K (Item 2.02) with Q2 2026 financial results and program updates across Beam’s base-editing pipeline and hematology franchise.
Ticker impact
Beam reported Q2 2026 results, dosed the first patient in the BEAM-302 pivotal cohort, and said a risto-cel BLA is expected by year-end 2026.
Bullish bias with potential volatility into ERS Congress and around any updates to pivotal enrollment pace and BLA timing.
The filing adds multiple time-bound clinical and regulatory milestones (first pivotal dose, IND clearance, dosing completion, BLA timing) alongside cash runway into mid-2029, which can re-rate risk for a pre-revenue biotech.
Market effects
Reinforces investor focus on base-editing and LNP delivery platforms, with AATD and PKU programs adding incremental regulatory and clinical momentum.
Limited direct regional spillover; primary impact is on US-listed biotech sentiment.
ERS Congress late-breaking selection can draw international attention to AATD gene-editing progress.
Counterpoint
Milestones are progress updates, not efficacy readouts; without new efficacy endpoints, the market may fade the news after initial enthusiasm.
Key entities
- issuerBeam Therapeutics Inc.
Nasdaq-listed biotech advancing base editing and LNP delivery; reported Q2 2026 results and multiple clinical/regulatory milestones.
- clinical_programBEAM-302
Lead AATD program; first patient dosed in the global pivotal cohort and updated data selected for late-breaking oral presentation at ERS 2026.
- clinical_programBEAM-304
PKU program; FDA cleared the IND and Beam initiated Phase 1/2 start-up activities.
- clinical_programRisto-cel (ristoglogene autogetemcel)
Autologous cell therapy for sickle cell disease; dosing complete in BEACON and BLA expected as early as year-end 2026.
- financingSixth Street facility
Beam expects an additional $200 million draw to extend funding into mid-2029.
